Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has therefore raised a total of 36.5 million francs, as was reported in a press release. A new addition to...

Over the last two decades, biopharmaceutical manufacturers have faced new obstacles in the market access of their products. The increasing development costs, shifting influences between stakeholders, and growing pharmaceutical competition are just some of the factors that are reshaping pharma’s market access. In an increasingly...

Tolremo therapeutics AG, the Swiss biotechnology company developing resistance-preventing precision therapies for patients with cancer, announces an additional fundraise bringing the Series A round total to CHF 13.7M. This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining...

Polyneuron has been granted the orphan drug designation by the US FDA to PN-1007 in the treatment of anti-MAG neuropathy, a disabling chronic disorder of the peripheral nervous system. This announcement follows the same designation from the European Medicines Agency in July 2017. The orphan drug...

PharmaBiome AG, a pioneer in next-generation microbiome therapies recently extended its recent capital increase to a total of CHF 2.15 million. The proceeds will support the advancement of their lead product towards clinical trials in ulcerative colitis. PharmaBiome also welcomed two new board members with extensive...

Alentis Therapeutics, the Basel-based biotech developing breakthrough treatments for fibrotic diseases, announced Dr. Roberto Iacone as Chief Executive Officer. Dr. Iacone is a physician-scientist with more than 15 years of experience in the life science industry. Before Alentis he was Global Head of Rare Diseases Research...

Versameb AG is a biopharmaceutical company developing next-generation RNA-based therapeutics. The company’s unique proprietary technology platform generates molecules optimized for improved secretion and modulation of several therapeutic targets. The company has just announced a seed round of CHF 6 million that is intended for the...

We are very pleased to welcome CSL Behring, one of the largest biotech companies in the world, as a partner in BaseLaunch Phase II. Read the full press release to hear more on the partnership, and the three strategic platforms that CSL Behring is currently focusing...

T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led by existing investors, including the Boehringer Ingelheim Venture Fund, Reference Capital SA, Wille Finance AG and private investors. The company has raised over 40...